Divyani Pandey has stepped into a pivotal leadership role at Sun Pharma as Product Manager in the diabetes division, further solidifying her growing footprint in the pharmaceutical marketing space. Based in Mumbai, she now helms the brand strategy for Istamet D — a cutting-edge oral anti-diabetic drug combining Dapagliflozin, Sitagliptin, and Metformin — a flagship brand for Sun Pharma’s fast-expanding diabetes portfolio.
In her current role at Sun Pharmaceutical Industries Ltd, Divyani blends scientific insight with strategic storytelling. Her responsibilities span crafting evidence-based brand campaigns, leading digital HCP engagement initiatives, and executing field force training modules tailored to empower medical representatives with confidence and clarity. Her dynamic approach to brand building, deeply rooted in market insights and clinical relevance, reflects a strong alignment with the company’s patient-centric mission.
Before joining Sun Pharma in July 2023, Divyani made her mark at Mankind Pharma Ltd as a Senior Product Executive. There, she was instrumental in driving the success of Jusoza M and Nobeglar, contributing to Mankind’s foray into DMF-grade combinations and long-acting insulin therapies. From MR engagement and product launches to hands-on training, she ensured a 360-degree marketing effort that connected scientific messaging with practical clinical value.
Divyani’s early years in pharma marketing include impactful tenures at Koye Pharmaceuticals and Medicom Healthcare, where she managed OAD and cardio-metabolic portfolios while also pioneering digital and e-commerce initiatives in niche therapeutic areas. Her foundation in pharmaceutical marketing was laid with practical exposure at Alembic Pharmaceuticals, rounding out a journey that exemplifies growth, adaptability, and strategic foresight.
With a track record defined by innovation, data-driven communication, and cross-functional execution, Divyani Pandey’s new role at Sun Pharma signals a promising future for the diabetes division. Her leadership is set to amplify the brand’s market impact while continuing to enhance patient outcomes in the ever-evolving landscape of chronic care.